Pulmonary Alveolar Microlithiasis Coexisting With Rheumatic Heart Disease and Severe Pulmonary Hypertension: A Case Report
Abstract
Pulmonary Alveolar Microlithiasis (PAM) is a rare diffuse lung disease characterized by intra-alveolar calcium phosphate microlith accumulation. Its coexistence with rheumatic valvular heart disease with resultant severe pulmonary hypertension is exceedingly uncommon and poses unique diagnostic and management challenges. This case underscores the importance of maintaining a broad differential diagnosis, emphasizing that new or worsening respiratory symptoms in patients with established cardiac disease should not be automatically attributed to cardiac pathology alone. We report the case of a 63-year-old gentleman with longstanding rheumatic heart disease (RHD) who presented with progressive dyspnoea. Clinical evaluation revealed features suggestive of severe pulmonary hypertension. Investigations confirmed PAM with characteristic "sandstorm" calcifications on chest imaging, supported by bronchoalveolar lavage demonstrating calcospherites and identification of an SLC34A2 gene mutation, alongside rheumatic mitral stenosis. The patient's pulmonary hypertension was attributed to a combination of PAM and RHD. This case illustrates a rare combination of PAM with RHD and severe pulmonary hypertension. It underlines the importance of considering dual pathology in patients with complex cardiopulmonary presentations. Early recognition of PAM, even in the presence of another disease like RHD, is crucial for appropriate management and prognostication. This report adds to the limited…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.